Analysts Downplay Intellia Adverse Event, but Gene Therapy Safety Remains Under Scrutiny on May 30, 2025 Adverse event ATTR-CM Event Gene Modification gene therapy Intellia liver transaminase MAGNITUDE trial Response process Safety Stock Decline +
Analysts Downplay Intellia Adverse Event, but Gene Therapy Safety Remains Under Scrutiny on May 30, 2025 Adverse event ATTR-CM Event Gene Modification gene therapy Intellia liver transaminase MAGNITUDE trial Response process Safety Stock Decline +